Clinical trial

Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery

NCT07515027

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Prophylactic administration of dolasetron Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Electroacupuncture Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Sham electroacupuncture Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery

Design: INTERVENTIONAL · Status: RECRUITING · Phase: NA

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-04-07

PhaseNA

Conditions

PONVunresolved

Interventions

Prophylactic administration of dolasetronDRUG

ElectroacupunctureOTHER

Sham electroacupunctureOTHER

Sponsors & collaborators

Shanghai Chest Hospitallead sponsor

Mapped research locations

ShanghaiChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07515027 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.